Efficient cell fusion process

Claim 2

A process for the preparation of monoclonal antibody-producing hybridomas which comprises: mixing together in vitro (a) tumor cells from a WIL2-NS human lymphoblastoid cell line, Accession No. ATCC-CRL 8155, which do not secrete immunoglobulin or infectious virus; and (b) peripheral blood lymphocytes obtained from a donor suffering from systemic lupus erythematosis, cultured in vitro with rabbit thymus extract and a polyclonal lymphocyte activator selected from the group consisting of pokeweed mitogen and lipopolysaccharides; substantially removing at least calcium ions from the cell environment, whereby to destabilize the membranes of said cells; adding a fusogen selected from the group consisting of phosphoglycerides and sterols to said destabilized cells; diluting the mixture of fusogen and destabilized cells with tissue culturer medium containing polyvalent cations; whereby to obtain said hybridomas by fusion of said tumor cells and said lymphocytes; and separating and reproducing said hybridomas.

Claim 3

A process for the preparation of monoclonal antibody-producing hybridomas which comprises: mixing together in vitro (a) tumor cells from a WIL2-NS human lymphoblastoid cell line, Accession No. ATCC-CRL 8155, which do not secrete immunoglobulin or infectious virus; and (b) peripheral blood lymphocytes obtained from a normal donor, cultured in vitro with sheep red blood cells and pokeweed mitogen as a polyclonal stimulant; substantially removing at least calcium ions from the cell environment whereby to destabilize the membranes of said cells; adding a fusogen selected from the group consisting of phosphoglycerides and sterols to said destabilized cells; diluting the mixture of fusogen and destabilized cells with tissue culture medium containing polyvalent cations; whereby to obtain said hybridomas by fusion of said tumor cells and said lymphocytes; and separating and reproducing said hybridomas.

Claim 4

A process for the preparation of monoclonal antibody-producing hybridomas which comprises: mixing together in vitro (a) tumor cells from a WIL2-NS human lymphoblastoid cell line, Accession No. ATCC-CRL 8155, which do not secrete immunoglobulin or infectious virus; and (b) peripheral blood lymphocytes obtained from a normal donor, cultured in vitro with sheep red blood cells and pokeweed mitogen as a polyclonal stimulant; substantially removing at least calcium ions from the cell environment whereby to destabilize the membranes of said cells; adding a fusogen selected from the group consisting of phosphoglycerides and sterols to said destabilized cells; diluting the mixture of fusogen and destabilized cells with tissue culture medium containing polyvalent cations; whereby to obtain said hybridomas by fusion of said tumor cells and said lymphocytes; and separating and reproducing said hybridomas.

Claim 5

A process for the preparation of monoclonal antibody-producing hybridomas which comprises: mixing together in vitro (a) tumor cells from WIL2-NS human lymphoblastoid cell line, Accession No. ATCC-CRL 8155, which do not secrete immunoglobulin or infectious virus; and (b) peripheral blood lymphocytes obtained from a normal donor, cultured in vitro with culture supernatant from a mouse myeloma line secreting IgG2a antibody, and lipopolysaccharide as a polyclonal stimulant; substantially removing at least calcium ions from the cell environment, whereby to destabilize the membrane of said cells; adding a fusogen selected from the group consisting of phosphogylcerides and sterols to said destabilized cells; diluting the mixture of fusogen and destabilized cells with tissue culture medium containing polyvalent cations; whereby to obtain said hybridomas by fusion of said tumor cells and said lymphocytes; and separating and reproducing said hybridomas.

Claim 6

A process for the preparation of monoclonal antibody-producing hybridomas which comprises: mixing together in vitro (a) tumor cells from WIL2-NS human lymphoblastoid cell line, Accession No. ATCC-CRL 8155, which do not secrete immunoglobulin or infectious virus; and (b) peripheral blood lymphocytes obtained from a normal donor, cultured in vitro with culture supernatant from a mouse myeloma line secreting IgG2a antibody, and lipopolysaccharide as a polyclonal stimulant; substantially removing at least calcium ions from the cell environment, whereby to destabilize the membrane of said cells; adding a fusogen selected from the group consisting of phosphogylcerides and sterols to said destabilized cells; diluting the mixture of fusogen and destabilized cells with tissue culture medium containing polyvalent cations; whereby to obtain said hybridomas by fusion of said tumor cells and said lymphocytes; and separating and reproducing said hybridomas.

Claim 7

A process for the preparation of monoclonal antibody-producing hybrodimas which comprises: mixing together in vitro (a) tumor cells from a WIL2-NS human lymphblastoid cell line, Accession No. ATCC-CRL 8155, which do not secrete immunoglobulin or infectious virus; and (b) peripheral blood lymphocytes obtained from a donor suffereing from systemic lupus erythematosis, cultured in vitro with lipopolysaccharide as a polyclonal stimulant; substantially removing at least calcium ions from the cell environment, whereby to destabilize the membranes of said cells; adding a fusogen selected from the group consisting of phosphoglycerides and sterols to said destabilized cells; diluting the mixture of fusogen and destabilized cells with tissue culture medium containing polyvalent cations; whereby to obtain said hybridomas by fusion of said tumor cells and said lymphocytes; and separating and reproducing said hybridomas.

Claim 8

A process for the preparation of monoclonal antibody-producing hybrodimas which comprises: mixing together in vitro (a) tumor cells from a WIL2-NS human lymphblastoid cell line, Accession No. ATCC-CRL 8155, which do not secrete immunoglobulin or infectious virus; and (b) peripheral blood lymphocytes obtained from a donor suffereing from systemic lupus erythematosis, cultured in vitro with lipopolysaccharide as a polyclonal stimulant; substantially removing at least calcium ions from the cell environment, whereby to destabilize the membranes of said cells; adding a fusogen selected from the group consisting of phosphoglycerides and sterols to said destabilized cells; diluting the mixture of fusogen and destabilized cells with tissue culture medium containing polyvalent cations; whereby to obtain said hybridomas by fusion of said tumor cells and said lymphocytes; and separating and reproducing said hybridomas.

Claim 9

A process for the preparation of monoclonal antibody-producing hybridomas which comprises: mixing together in vitro (a) tumor cells from a WIL2-NS human lymphoblastoid cell line, Accession No. ATCC-CRL 8155, which do not secrete immunoglobulin or infectious virus; and (b) peripheral blood lymphocytes obtained from a donor suffereing from systemic lupus erythematosis, cultured in vitro with purified DNA and lipopolysaccharide as a polyclonal stimulant; substantially removing at least calcium ions from the cell environment to destabilize the membranes of said cells; adding a fusogen selected from the group consisting of phosphoglycerides and sterols to said destabilized cells; diluting the mixture of fusogen and destabilized cells with tissue culture medium containing polyvalent cations; whereby to obtain said hybridomas by fusion of said tumor cells and said lymphocytes; and separating and reproducing said hybridomas.

Claim 10

A process for the preparation of monoclonal antibody-producing hybridomas which comprises: mixing together in vitro (a) tumor cells from a WIL2-NS human lymphoblastoid cell line, Accession No. ATCC-CRL 8155, which do not secrete immunoglobulin or infectious virus; and (b) peripheral blood lymphocytes obtained from a donor suffereing from systemic lupus erythematosis, cultured in vitro with purified DNA and lipopolysaccharide as a polyclonal stimulant; substantially removing at least calcium ions from the cell environment to destabilize the membranes of said cells; adding a fusogen selected from the group consisting of phosphoglycerides and sterols to said destabilized cells; diluting the mixture of fusogen and destabilized cells with tissue culture medium containing polyvalent cations; whereby to obtain said hybridomas by fusion of said tumor cells and said lymphocytes; and separating and reproducing said hybridomas.

Claim 11

A process for the preparation of interferon-producing hybridomas which comprises: mixing together in vitro (a) tumor cells from a WIL2-NS human lymphoblastoid cell line, Accession No. ATCC-CRL 8155, which do not secrete immunoglobulin or infectious virus; and (b) peripheral blood lymphocytes obtained from a normal donor, cultured in vitro with Concanavalin A; substantially removing at least calcium ions from the cell environment to destabilize the membranes of said cells; adding a fusogen selected from the group consisting of phosphoglycerides and sterols to said destabilized cells; diluting the mixture of fusogen and destabilized cells with tissue culture medium containing polyvalent cations; whereby to obtain said hybridomas by fusion of said tumor cells and said lymphocytes; and separating and reproducing said hybridomas.

Claim 12

A process for the preparation of interferon-producing hybridomas which comprises: mixing together in vitro (a) tumor cells from a WIL2-NS human lymphoblastoid cell line, Accession No. ATCC-CRL 8155, which do not secrete immunoglobulin or infectious virus; and (b) peripheral blood lymphocytes obtained from a normal donor, cultured in vitro with Concanavalin A; substantially removing at least calcium ions from the cell environment to destabilize the membranes of said cells; adding a fusogen selected from the group consisting of phosphoglycerides and sterols to said destabilized cells; diluting the mixture of fusogen and destabilized cells with tissue culture medium containing polyvalent cations; whereby to obtain said hybridomas by fusion of said tumor cells and said lymphocytes; and separating and reproducing said hybridomas.

Claim 13

A process for the preparation of human growth hormone-producing hybridomas which comprises: mixing togehter in vitro (a) tumor cells from a WIL2-NS human lymphoblastoid cell line, Accession No. ATCC-CRL 8155, which do not secrete immunoglobulin or infectious virus; and (b) normal human pituitary cells, cultured in vitro; substantially removing at least calcium ions from the cell environment to destabilize the membranes of said cells; adding a fusogen selected from the group consisting of phosphoglycerides and sterols to said destabilized cells; diluting the mixture f fusogen and destabilized cells with tissue culture medium containing polyvalent cations; whereby to obtains aid hydridomas by fusion of said tumor cells and said lymphocytes; and separating and reproducing said hybridomas.

Claim 14

A process for the preparation of human growth hormone-producing hybridomas which comprises: mixing togehter in vitro (a) tumor cells from a WIL2-NS human lymphoblastoid cell line, Accession No. ATCC-CRL 8155, which do not secrete immunoglobulin or infectious virus; and (b) normal human pituitary cells, cultured in vitro; substantially removing at least calcium ions from the cell environment to destabilize the membranes of said cells; adding a fusogen selected from the group consisting of phosphoglycerides and sterols to said destabilized cells; diluting the mixture f fusogen and destabilized cells with tissue culture medium containing polyvalent cations; whereby to obtains aid hydridomas by fusion of said tumor cells and said lymphocytes; and separating and reproducing said hybridomas.

Claim 15

A process for the preparation of monoclonal antibody-producing hybridomas which comprises: mixing together in vitro (a) tumor cells from a WIL2-NS human lymphoblastoid cell line, Accession No. ATCC-CRL 8155, which do not secrete immunoglobuline or infectious virus; and (b) peripheral blood lymphocytes obtained from a normal donor, cultured in vitro with human neuroblastoma bumor cells and pokeweed mitogen as a polyclonal stimulant; substantially removing at least calcium ions from the cell environment to destabilize the membranes of said cells; adding a fusogen selected from the group consisting of phosphoglycerides and sterols to said destabilized cells; diluting the mixture of fusogne and destabilized cells with tissue culture medium containing polyvalent cations; whereby to obtain said hybridomas by fusion of said tumor cells and said lymphocytes; and separating and reproducing said hybridomas.

Claim 16

A process for the preparation of monoclonal antibody-producing hybridomas which comprises: mixing together in vitro (a) tumor cells from a WIL2-NS human lymphoblastoid cell line, Accession No. ATCC-CRL 8155, which do not secrete immunoglobuline or infectious virus; and (b) peripheral blood lymphocytes obtained from a normal donor, cultured in vitro with human neuroblastoma bumor cells and pokeweed mitogen as a polyclonal stimulant; substantially removing at least calcium ions from the cell environment to destabilize the membranes of said cells; adding a fusogen selected from the group consisting of phosphoglycerides and sterols to said destabilized cells; diluting the mixture of fusogne and destabilized cells with tissue culture medium containing polyvalent cations; whereby to obtain said hybridomas by fusion of said tumor cells and said lymphocytes; and separating and reproducing said hybridomas.

Claim 17

A process for the preparation of monoclonal antibody-producing microcell transerted tumor cells which comprises: substantially removing at least calcium ions from a culture of tumor cells from a WIL2-S human lymphoblastoid cell line, Accession No. ATCC-CRL 8885, which do not secrete immunoglobulin or infectious virus, whereby to destabilize the membranes of said tumor cells; mixing together in vitro (a) the destabilized tumor cells; (b) microcells comprising at lest one chromosome surrounded by nuclear membrane material derived from peripheral blood lymphocytes obtained from a normal donor, cultured in vitro with pokeweed mitogen as a polyclonal lymphocyte activator; and (c) a fusogen selected from the group consisting of phosphoglycerides and sterols; whereby to transert said microcells into said tumor cells; diluting the resulting microcell transerted tumor cells with tissue culture medium containing polyvalent cations; and separating and reproducing said microcell transerted tumor cells.

Claim 18

A process for the preparation of monoclonal antibody-producing microcell transerted tumor cells which comprises: substantially removing at least calcium ions from a culture of tumor cells from a WIL2-S human lymphoblastoid cell line, Accession No. ATCC-CRL 8885, which do not secrete immunoglobulin or infectious virus, whereby to destabilize the membranes of said tumor cells; mixing together in vitro (a) the destabilized tumor cells; (b) microcells comprising at lest one chromosome surrounded by nuclear membrane material derived from peripheral blood lymphocytes obtained from a normal donor, cultured in vitro with pokeweed mitogen as a polyclonal lymphocyte activator; and (c) a fusogen selected from the group consisting of phosphoglycerides and sterols; whereby to transert said microcells into said tumor cells; diluting the resulting microcell transerted tumor cells with tissue culture medium containing polyvalent cations; and separating and reproducing said microcell transerted tumor cells.

Claim 19

A process for the preparation of monoclonal antibody-producing microcell transerted tumor cells which comprises: substantially removing at least calcium ions from a culture of tumor cells from a WIL2-S human lymphoblastoid cell line, Accession No. ATCC-CRL 8885, which do not secrete immunoglobulin or infectious virus, whereby to destabilize the membranes of said tumor cells; mixing together in vitro (a) the destabilized tumor cells; (b) microcells comprising at least one chromosome surrounded by nuclear membrane material derived from peripheral blood lymphocytes obtained from a normal donor, cultured in vitro with the F(ab')2 fragment of mouse IgG antibody and pokeweed mitogen as a polyclonal lymphocyte activator; and (c) a fusogen selected from the group consisting of phosphoglycerides and sterols; whereby to transert said microcells into said tumor cells; diluting the resulting microcell transerted tumor cells with tissue cultue medium containing polyvalent cations; and separating and reproducing said microcell transerted tumor cells.

Claim 20

A process for the preparation of monoclonal antibody-producing microcell transerted tumor cells which comprises: substantially removing at least calcium ions from a culture of tumor cells from a WIL2-S human lymphoblastoid cell line, Accession No. ATCC-CRL 8885, which do not secrete immunoglobulin or infectious virus, whereby to destabilize the membranes of said tumor cells; mixing together in vitro (a) the destabilized tumor cells; (b) microcells comprising at least one chromosome surrounded by nuclear membrane material derived from peripheral blood lymphocytes obtained from a normal donor, cultured in vitro with the F(ab')2 fragment of mouse IgG antibody and pokeweed mitogen as a polyclonal lymphocyte activator; and (c) a fusogen selected from the group consisting of phosphoglycerides and sterols; whereby to transert said microcells into said tumor cells; diluting the resulting microcell transerted tumor cells with tissue cultue medium containing polyvalent cations; and separating and reproducing said microcell transerted tumor cells.

Claim 21

A process for the preparation of monoclonal antibody-producing microcell transerted tumor cells which comprises: substantially removing at least calcium ions from a culture of tumor cells from a HS Sultan human lymphoblastoid cell line, Accession No. ATCC-CRL 1484, which do not secrete immunoglobulin or infectious virus, whereby to destabilize the membranes of said tumor cells; mixing together in vitro (a) the destabilized tumor cells; (b) microcells comprising at least one chromosome surrounded by nuclear membrane material derived from peripheral blood lymphocytes obtained from a donor suffering from systemic lupus erythematosis, cultured in vitro with an antigen selected from the group consisting of the beta subunit of human chorionic gonadotropin and the F(ab')2 fragment of mouse IgG and pokeweed mitogen as a polyclonal lymphocyte activator; and (c) a fusogen selected from the group consisting of phosphoglycerides and sterols; whereby to transert said microcells into said tumor cells; diluting the resulting microcell transerted tumor cells with tissue culture medium containing polyvalent cations; and separating and reproducing said microcell transerted tumor cells.

Claim 22

A process for the preparation of monoclonal antibody-producing microcell transerted tumor cells which comprises: substantially removing at least calcium ions from a culture of tumor cells from a HS Sultan human lymphoblastoid cell line, Accession No. ATCC-CRL 1484, which do not secrete immunoglobulin or infectious virus, whereby to destabilize the membranes of said tumor cells; mixing together in vitro (a) the destabilized tumor cells; (b) microcells comprising at least one chromosome surrounded by nuclear membrane material derived from peripheral blood lymphocytes obtained from a donor suffering from systemic lupus erythematosis, cultured in vitro with an antigen selected from the group consisting of the beta subunit of human chorionic gonadotropin and the F(ab')2 fragment of mouse IgG and pokeweed mitogen as a polyclonal lymphocyte activator; and (c) a fusogen selected from the group consisting of phosphoglycerides and sterols; whereby to transert said microcells into said tumor cells; diluting the resulting microcell transerted tumor cells with tissue culture medium containing polyvalent cations; and separating and reproducing said microcell transerted tumor cells.